Loading...
XSHE002932
Market cap535mUSD
Jan 10, Last price  
17.60CNY
1D
-6.68%
1Q
0.28%
IPO
53.44%
Name

Wuhan Easy Diagnosis Biomedicine Co Ltd

Chart & Performance

D1W1MN
XSHE:002932 chart
P/E
52.38
P/S
5.24
EPS
0.34
Div Yield, %
14.84%
Shrs. gr., 5y
5.13%
Rev. gr., 5y
33.56%
Revenues
750m
-92.88%
1,218,0517,096,03325,947,47857,802,45495,341,627140,979,148165,123,343176,381,394181,155,372959,099,1962,829,829,54610,530,277,815749,536,774
Net income
75m
-98.22%
253,2391,401,8697,322,14221,539,67035,596,51559,692,00065,492,64761,419,87541,525,796468,927,7941,413,224,4344,208,496,91374,925,916
CFO
392m
-90.22%
01,032,5766,296,10016,474,00045,021,65058,859,24246,496,34553,671,44622,485,878359,682,4491,127,006,1474,012,848,413392,498,061
Dividend
May 28, 20240.12 CNY/sh
Earnings
May 16, 2025

Profile

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and diagnostic equipment in China and internationally. Its products portfolio includes molecular diagnostic products, such as drug metabolism genetic testing and pathogen nucleic acid detection kits; and immunodiagnostic and blood gas diagnosis products. The company also provides emergency and critical illness information solutions, including information software products, supporting hardware, and certification consulting services; and third-party medical inspection services. It offers products in the areas of cardiovascular, kidney, infectious, diabetes, endocrine and metabolic, obstetrics, and gynecology diseases, as well as prenatal and postnatal care, health checkups, thyroid, hormones, blood gas, coagulation, drug metabolism, pathogen detection. The company was founded in 2008 and is based in Wuhan, China.
URL
http://www.mdeasydiagnosis.com/
IPO date
Jul 10, 2018
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
749,537
-92.88%
10,530,278
272.12%
Cost of revenue
619,775
4,360,510
Unusual Expense (Income)
NOPBT
129,762
6,169,768
NOPBT Margin
17.31%
58.59%
Operating Taxes
70,673
695,926
Tax Rate
54.46%
11.28%
NOPAT
59,089
5,473,842
Net income
74,926
-98.22%
4,208,497
197.79%
Dividends
(582,483)
(548,772)
Dividend yield
11.17%
6.13%
Proceeds from repurchase of equity
(532)
BB yield
0.01%
Debt
Debt current
23,614
182,842
Long-term debt
36,505
41,504
Deferred revenue
14,260
5,960
Other long-term liabilities
3,034
1
Net debt
(1,111,922)
(4,283,969)
Cash flow
Cash from operating activities
392,498
4,012,848
CAPEX
(109,974)
Cash from investing activities
(1,365,066)
Cash from financing activities
(670,060)
FCF
451,427
4,797,519
Balance
Cash
1,138,272
4,508,316
Long term investments
33,769
Excess cash
1,134,564
3,981,802
Stockholders' equity
4,856,876
5,919,199
Invested Capital
5,216,697
2,834,450
ROIC
1.47%
285.74%
ROCE
2.03%
90.15%
EV
Common stock shares outstanding
227,048
232,728
Price
22.97
-40.24%
38.44
15.33%
Market cap
5,215,298
-41.70%
8,946,048
26.78%
EV
4,369,588
4,933,966
EBITDA
213,161
6,228,846
EV/EBITDA
20.50
0.79
Interest
10,499
3,423
Interest/NOPBT
8.09%
0.06%